2025
Exogenous pyruvate is therapeutic against colitis by targeting cytosolic phospholipase A2
Hasan S, Ghani N, Zhao X, Good J, Liu C. Exogenous pyruvate is therapeutic against colitis by targeting cytosolic phospholipase A2. Genes & Diseases 2025, 12: 101571. DOI: 10.1016/j.gendis.2025.101571.Peer-Reviewed Original ResearchInflammatory bowel diseaseUlcerative colitisBowel diseaseDextran sodium sulfate-induced colitisChronic inflammatory bowel diseaseUlcerative colitis pathogenesisTight junction proteinsPhase of inflammationCytosolic phospholipase A2Immune dysregulationColitis pathogenesisReal-time PCRNFkB translocationCellular metabolitesColon histologyJunction proteinsInflammatory diseasesColitis modelQuantitative real-time PCRTherapeutic effectUlcerative colitis modelAction of pyruvateImmunofluorescence stainingColitisRNA sequencing analysisMonitoring Inflammatory Bowel Disease Activity: When, How and Why.
Gaidos J, Hashash J. Monitoring Inflammatory Bowel Disease Activity: When, How and Why. The American Journal Of Gastroenterology 2025 PMID: 40488637, DOI: 10.14309/ajg.0000000000003582.Peer-Reviewed Original ResearchInflammatory bowel diseaseActive intestinal inflammationIntestinal inflammationIBD careInflammatory bowel disease managementControl of inflammationMeasures of inflammationLack of symptomsPresence of symptomsTime of evaluationClinical remissionDisease remissionDisease activityClinical endpointsClinical symptomsTreatment endpointRadiographic assessmentCrohn's diseaseIntestinal ultrasoundBiochemical markersUlcerative colitisBowel diseaseAssociation of Primary Language with Treatment and Outcomes in Inflammatory Bowel Disease.
Sahyoun L, Chavez V, Vasudevan J, Kogan L, Mukkamala B, Ochi M, Anand T, Ahmed Z, Tang Z, Feagins L, Gaidos J. Association of Primary Language with Treatment and Outcomes in Inflammatory Bowel Disease. Clinical And Translational Gastroenterology 2025 PMID: 40478247, DOI: 10.14309/ctg.0000000000000868.Peer-Reviewed Original ResearchCorticosteroid-free clinical remissionInflammatory bowel diseaseAdvanced therapiesClinical remissionDisease activityCohort study of adult patientsBowel diseaseStudy of adult patientsElevated fecal calprotectinBaseline disease activityPhysician global assessmentIBD disease activityRates of inflammatory bowel diseaseFecal calprotectinAdult patientsTherapy useCohort studyPrimary outcomeMultivariate analysisSecondary outcomesMulti-centerClinic visitsDisease outcomePatientsBaseline differencesThe role of tight junctions in the pathogenesis of inflammatory bowel disease: immune modulation and barrier dysfunction
Heo J, Kim M, Yang Y, Choi H, Kim K, Oh T, Yang J, Kim Y, Park K. The role of tight junctions in the pathogenesis of inflammatory bowel disease: immune modulation and barrier dysfunction. Molecular & Cellular Toxicology 2025, 21: 495-506. DOI: 10.1007/s13273-025-00545-y.Peer-Reviewed Original ResearchInflammatory bowel diseaseIncreased epithelial permeabilityPathogenesis of inflammatory bowel diseaseBowel diseaseTight junctionsEpithelial permeabilityDisease progressionTherapeutic strategiesDisruption of tight junctionsRelease of proinflammatory cytokinesTumor necrosis factor-alphaPathophysiology of inflammatory bowel diseaseTight junction dysfunctionTight junction regulationTight junction disruptionTight junction integrityTight junction structureImmune cell activationMucosal immune systemRegulate paracellular transportNecrosis factor-alphaIntestinal tight junctionsInflammatory bowel disease managementNuclear factor kappa BInterleukin-1 betaTreat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial
Singh S, Nguyen J, Fudman D, Gerich M, Shah S, Hudesman D, McConnell R, Lukin D, Flynn A, Hwang C, Sprung B, Gaidos J, Mattar M, Rubin D, Hashash J, Metwally M, Ali T, Ma C, Hoentjen F, Narula N, Bessissow T, Rosenfeld G, McCurdy J, Ananthakrishnan A, Cross R, Gaytan J, Gurrola E, Patel S, Siegel C, Melmed G, Weaver S, Power S, Zou G, Jairath V, Hou J. Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial. BMJ Open Gastroenterology 2025, 12: e001615. PMID: 40164445, PMCID: PMC11962770, DOI: 10.1136/bmjgast-2024-001615.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseAdvanced therapiesTreat-to-targetSymptomatic remissionBowel inflammationOpen-labelAsymptomatic patientsPatient-Centered Outcomes Research InstituteBowel diseaseControlled TrialsSafety of switchingClinical practiceActive bowel inflammationReduced bowel inflammationDeep remissionEndoscopic remissionTreatment failurePrimary endpointRandomised controlled trialsTargeted immunomodulationRemissionTherapyPatientsGood clinical practiceInformed consentAssociations of TNF-Α -308 and -238 Polymorphisms with Inflammatory Bowel Disease: A Case-Control Study and Meta-Analysis of Published Data
Moosavi S, Shanker A, Sadr M, Soltani S, Shahkarami S, Farhadi E, Daryani N, Noveiry B, Varzaneh F, Bashashati M, Rezaei N. Associations of TNF-Α -308 and -238 Polymorphisms with Inflammatory Bowel Disease: A Case-Control Study and Meta-Analysis of Published Data. Immunology And Genetics Journal 2025 DOI: 10.18502/igj.v8i2.18003.Peer-Reviewed Original ResearchInflammatory bowel diseaseSingle nucleotide polymorphismsTNF-aMeta-analysisGene polymorphismsChronic relapsing-remitting inflammatory diseaseHealthy controlsBowel diseaseTumor necrosis factor-alphaAssociated with inflammatory bowel diseaseSusceptibility to inflammatory bowel diseasePathogenesis of inflammatory bowel diseaseNecrosis factor-alphaCase-control studySequence-specific primersFactor-alphaIranian patientsPolymerase chain reactionPCR-SSPInflammatory diseasesGenotype statusNucleotide polymorphismsAllele frequenciesCase-controlPatientsColorectal Neoplasia in Inflammatory Bowel Disease
Al Sulais E, AlAmeel T, Alenzi M, Shehab M, AlMutairdi A, Al-Bawardy B. Colorectal Neoplasia in Inflammatory Bowel Disease. Cancers 2025, 17: 665. PMID: 40002259, PMCID: PMC11853504, DOI: 10.3390/cancers17040665.Peer-Reviewed Original ResearchRisk of colonic neoplasiaColonic neoplasiaInflammatory bowel diseaseConcomitant primary sclerosing cholangitisRisk factorsMultiple risk factorsColorectal neoplasiaBowel diseaseHigh-risk featuresIncreased riskPrimary sclerosing cholangitisColonic Crohn's diseaseColonic dysplasiaDisease extentSclerosing cholangitisRiskCrohn's diseaseNeoplasiaUlcerative colitisDiseaseSurveillancePatientsColorectalEpidemiologySleep Deficiency and Fatigue in Adults with Inflammatory Bowel Disease: A Systematic Review
Conley S, Hwang Y, Al-Saleh S, Kamp K, Cahalan A, Redeker N. Sleep Deficiency and Fatigue in Adults with Inflammatory Bowel Disease: A Systematic Review. Western Journal Of Nursing Research 2025, 47: 292-307. PMID: 39882819, DOI: 10.1177/01939459251314941.Peer-Reviewed Original ResearchConceptsSystematic reviewSleep qualityAssociated with more severe fatigueFactors associated with fatigueSleep deficiencyAssociated with fatigueInflammatory bowel diseasePreferred Reporting ItemsPoor sleep qualitySelf-report questionnairesDiagnosis of inflammatory bowel diseaseMeasure fatigueImprove fatigueModifiable contributorReporting ItemsTreat fatigueBowel diseaseSevere fatigueSleep interventionsInclusion criteriaIntervention workDisabling symptomsAssessment of disease activityYounger ageInterventionSafety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS
Allegretti J, Feuerstadt P, Knapple W, Orenstein R, Pinton P, Sheh A, Khanna S. Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS. Inflammatory Bowel Diseases 2025, izae291. PMID: 39862395, DOI: 10.1093/ibd/izae291.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsRecurrent Clostridioides difficile infectionInflammatory bowel diseaseClostridioides difficile infectionWeeks of administrationPrevention of recurrent CDISerious treatment-emergent adverse eventsSubgroup analysisSustained clinical response ratesBowel diseaseSustained clinical responseClinical response rateModerate gastrointestinal symptomsUS Food and Drug AdministrationTreatment success rateFood and Drug AdministrationClinical responseSingle-doseProspective trialsFecal microbiotaEfficacy outcomesDifficile infectionAdverse eventsGastrointestinal symptomsTreatment successP1260 Demographics and Clinical Characteristics of Inflammatory Bowel Disease in the Middle East and North Africa : A Multi-Nation Cross-sectional (MIRAGE) Study
Shehab M, Azzam N, Al-Bawardy B, Abid S, Bashandi A, AlShihri R, Mukhtar M, Saadah O, Alharbi O, Al-Darmaki A, Al Harthi S, Al-Ejji K, Ayash A, Al sahli A, Khamees N, Salem O, Mohamed E, Maher M, Daba G, Helal A, Alnassar M, Alfadhli A, Mosli M. P1260 Demographics and Clinical Characteristics of Inflammatory Bowel Disease in the Middle East and North Africa : A Multi-Nation Cross-sectional (MIRAGE) Study. Journal Of Crohn's And Colitis 2025, 19: i2280-i2281. DOI: 10.1093/ecco-jcc/jjae190.1434.Peer-Reviewed Original ResearchInflammatory bowel disease patientsMiddle East and North Africa regionEpidemiology of inflammatory bowel diseaseInflammatory bowel diseaseJournal of EpidemiologyInflammatory bowel disease cohortPrevalence of inflammatory bowel diseaseClinical characteristics of inflammatory bowel diseaseCharacteristics of inflammatory bowel diseaseCD patientsBowel diseaseIBD-related surgeryChi-square testMulti-national studyInflammatory bowel disease centerMiddle East and North AfricaCrohn's diseaseRising PrevalenceUlcerative colitisFisher's exact testLeft-sided colitisDemographic characteristicsKingdom of Saudi ArabiaMiddle Eastern patientsIBD-ULupus and inflammatory bowel disease share a common set of microbiome features distinct from other autoimmune disorders
Zhou H, Balint D, Shi Q, Vartanian T, Kriegel M, Brito I. Lupus and inflammatory bowel disease share a common set of microbiome features distinct from other autoimmune disorders. Annals Of The Rheumatic Diseases 2025, 84: 93-105. PMID: 39874239, PMCID: PMC11868722, DOI: 10.1136/ard-2024-225829.Peer-Reviewed Original ResearchProtein-protein interaction analysisMicrobial signaturesMicrobial profilesEffector-like proteinsSignaling pathwayInterleukin-12 signaling pathwayDisease mechanismsBacteria-derived proteinsMetagenomic datasetsMicrobiome featuresMicrobial underpinningsFunctional genesMicrobial biomarkersInteraction analysisMicrobial influenceInflammatory bowel diseaseMicrobial mechanismsGlucocorticoid signalingProteinGlucocorticoid receptorCritical roleAutoimmune diseasesPathwayBowel diseasePotential importance
2024
Higher Rates of Delay in Starting Advanced Inflammatory Bowel Disease Therapies Linked to Insurance Delays, Intravenous Infusions, and Lack of Pharmacy Support
Gottesman S, Xiao K, Nguyen H, Hernandez E, Saweris E, Jagannathan P, Jafri F, Davis J, Tong K, Tang Z, Gaidos J, Feagins L. Higher Rates of Delay in Starting Advanced Inflammatory Bowel Disease Therapies Linked to Insurance Delays, Intravenous Infusions, and Lack of Pharmacy Support. Clinical And Translational Gastroenterology 2024, 16: e00808. PMID: 39718220, PMCID: PMC11932631, DOI: 10.14309/ctg.0000000000000808.Peer-Reviewed Original ResearchConceptsAdvanced therapiesRisk factorsMulticenter studyMulticenter study of patientsInflammatory bowel disease therapyStudy of patientsAdult inflammatory bowel diseasePatient-related factorsIntravenous drug deliverySmall molecule therapiesLogistic regression analysisInflammatory bowel diseaseBaseline demographicsDisease activityIntravenous infusionMolecule therapiesDisease characteristicsGastroenterology practiceTherapyBowel diseaseInsurance denialPatientsDoseIntravenous inductionCare teamSleep Deficiency A Symptoms Perspective: Exemplars from Chronic Heart Failure, Inflammatory Bowel Disease, and Breast Cancer
Redeker N, Conley S, Hwang Y. Sleep Deficiency A Symptoms Perspective: Exemplars from Chronic Heart Failure, Inflammatory Bowel Disease, and Breast Cancer. Sleep Medicine Clinics 2024, 19: 537-548. PMID: 39455175, DOI: 10.1016/j.jsmc.2024.07.003.Peer-Reviewed Original ResearchConceptsExcessive daytime sleepinessChronic heart failureInflammatory bowel diseaseBreast cancerHeart failureBowel diseaseContributions of sleep deficiencySleep disordersSleep deficiencyPrevalence of fatigueDaytime sleepinessDaytime symptomsChronic conditionsBreastCancerDeficiencySymptomsDiseaseSleepDisordersFatigueInflammatory bowel disease is associated with greater odds of complications following posterior lumbar fusion and further amplified for patients exposed to monoclonal antibody biologics
Seddio A, Katsnelson B, Smith-Voudouris J, Gouzoulis M, Day W, Jabbouri S, Vasudevan R, Rubio D, Grauer J. Inflammatory bowel disease is associated with greater odds of complications following posterior lumbar fusion and further amplified for patients exposed to monoclonal antibody biologics. North American Spine Society Journal (NASSJ) 2024, 20: 100574. PMID: 39759221, PMCID: PMC11697407, DOI: 10.1016/j.xnsj.2024.100574.Peer-Reviewed Original ResearchPosterior lumbar fusionInflammatory bowel diseaseOdds ratioNational Inpatient SampleElixhauser Comorbidity IndexLumbar fusionBowel diseaseKaplan-Meier survival analysisEmergency departmentInflammatory bowel disease patientsLog-rank testMinor adverse eventsNon-IBD patientsIn-hospital dataMultivariate logistic regressionAssociated with greater oddsElevated odds ratiosReoperation rateSurgical complicationsSpine surgeryInferior outcomesPearlDiver databasePost-discharge outcomesAdult patientsAdverse eventsExpression of IL-7RαlowCX3CR1+ CD8+ T Cells and α4β7 Integrin Tagged T Cells Related to Mucosal Immunity in Children with Inflammatory Bowel Disease
Yang D, Kim H, Dinh D, Yang J, Hyun C, Jee Y, Lee N, Shin M, Kang I, Kang K. Expression of IL-7RαlowCX3CR1+ CD8+ T Cells and α4β7 Integrin Tagged T Cells Related to Mucosal Immunity in Children with Inflammatory Bowel Disease. Pediatric Gastroenterology Hepatology & Nutrition 2024, 27: 345-354. PMID: 39563840, PMCID: PMC11570351, DOI: 10.5223/pghn.2024.27.6.345.Peer-Reviewed Original ResearchCD8<sup>+</sup> T cellsPeripheral blood mononuclear cellsCD4<sup>+</sup> T cellsInflammatory bowel diseaseT cellsUlcerative colitis groupCrohn's disease groupEffector memoryColitis groupControl groupEffector memory CD8<sup>+</sup> T cellsMemory CD8<sup>+</sup> T cellsCD8+ T cellsBowel diseaseEM CD8<sup>+</sup> T cellsTrafficking immune cellsDisease groupPathogenesis of ulcerative colitisBlood mononuclear cellsInflamed intestinal mucosaConcentrations of TNF-aIntestinal mucosaSerum levelsT lymphocytesImmune cellsEndoscopic diagnosis and management of adult inflammatory bowel disease: a consensus document from the American Society for Gastrointestinal Endoscopy IBD Endoscopy Consensus Panel
Panel T, Shen B, Abreu M, Cohen E, Farraye F, Fischer M, Feuerstadt P, Kapur S, Ko H, Kochhar G, Liu X, Mahadevan U, McBride D, Navaneethan U, Regueiro M, Ritter T, Sharma P, Lichtenstein G. Endoscopic diagnosis and management of adult inflammatory bowel disease: a consensus document from the American Society for Gastrointestinal Endoscopy IBD Endoscopy Consensus Panel. Gastrointestinal Endoscopy 2024, 101: 295-314. PMID: 39425706, DOI: 10.1016/j.gie.2024.08.034.Peer-Reviewed Original ResearchInflammatory bowel diseaseInflammatory bowel disease specialistsAssessment of treatment responseBowel diseaseClinical practice patternsConsensus documentMonitoring of disease activityAdult inflammatory bowel diseaseDysplasia surveillancePractice patternsGI pathologistsEndoscopic aspectDisease activityEndoscopic managementPostoperative evaluationConsensus panelTreatment responseInterventional therapyEndoscopic diagnosisIBD managementDiagnosisDiseaseCryptosporidiosis in individuals with inflammatory bowel disease: a scoping review protocol
Liu B, Schnider A, DeArmond M, Banach D, Haubrich B. Cryptosporidiosis in individuals with inflammatory bowel disease: a scoping review protocol. BMJ Open 2024, 14: e086529. PMID: 39414295, PMCID: PMC11481120, DOI: 10.1136/bmjopen-2024-086529.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseJoanna Briggs InstituteBowel diseaseAssociated with significant morbidityModerate-to-severe diarrheaPublished clinical literatureTreatment of cryptosporidiosisPeer-reviewed journalsImmunosuppressive therapyInstitutional review boardRisk of infectionSignificant morbidityImmunocompromised individualsTheses GlobalCrohn's diseaseGastrointestinal infectionsGrey literatureReview protocolRisk factorsAdult studiesCochrane LibrarySelf-limitingPatientsEpidemiological correlationReview teamLong-term Outcomes Following Colectomy and Liver Transplantation for Inflammatory Bowel Disease with Primary Sclerosing Cholangitis.
Matar A, Falconer E, LaBella M, Kapadia M, Justiniano C, Olortegui K, Steinhagen R, Schultz K, Pratap A, Leeds I, Weaver L, Gaertner W, Finger E, Thompson M, Fair L, Fichera A, Lovasik B, Chapman W, McGeoch C, Camacho M, Kazimi M, Kim S, Shaffer V, Srinivasan J. Long-term Outcomes Following Colectomy and Liver Transplantation for Inflammatory Bowel Disease with Primary Sclerosing Cholangitis. Annals Of Surgery 2024 PMID: 39258375, PMCID: PMC12184207, DOI: 10.1097/sla.0000000000006533.Peer-Reviewed Original ResearchTotal abdominal colectomyLong-term outcomesIleal pouch anal anastomosisMedically refractory diseaseLiver transplantationPSC-IBDRecurrent PSCRefractory diseaseBiliary complicationsMedian timeLong-term outcomes of patientsBowel diseasePost-LT survivalOutcomes of patientsPrimary sclerosing cholangitisFraction of patientsPSC-IBD patientsLong-term survivalInflammatory bowel diseasePost-LTSclerosing cholangitisPediatric patientsAbdominal colectomyEnd ileostomyLT survivalSaudi consensus guidance for the diagnosis and management of inflammatory bowel disease in children and adolescents
Saadah O, AlAmeel T, Al Sarkhy A, Hasosah M, Al-Hussaini A, Almadi M, Al-Bawardy B, Altuwaijri T, AlEdreesi M, Bakkari S, Alharbi O, Azzam N, Almutairdi A, Alenzi K, Al-Omari B, Almudaiheem H, Al-Jedai A, Mosli M. Saudi consensus guidance for the diagnosis and management of inflammatory bowel disease in children and adolescents. Saudi Journal Of Gastroenterology 2024, 31: 107-136. PMID: 39215473, PMCID: PMC12155459, DOI: 10.4103/sjg.sjg_171_24.Peer-Reviewed Original ResearchInflammatory bowel diseaseSociety of Clinical PharmacyAdolescents aged 6Saudi Ministry of HealthMinistry of HealthManagement of inflammatory bowel diseaseSaudi Gastroenterology AssociationSaudi Society of Clinical PharmacyPediatric inflammatory bowel diseaseClinical pharmacyGastroenterological AssociationAged 6Bowel diseaseSaudi MinistryGuideline statementsManagement of pediatric inflammatory bowel diseaseSaudi childrenConsensus guidanceAdolescentsChildrenSaudiSaudi societyHealthPharmacyDiagnosisGastrointestinal disease in systemic sclerosis: the neglected organ system?
McMahan Z, Pandolfino J, Perlman H, Del Galdo F, Hinchcliff M. Gastrointestinal disease in systemic sclerosis: the neglected organ system? Current Opinion In Rheumatology 2024, 36: 374-378. PMID: 39193877, PMCID: PMC11588520, DOI: 10.1097/bor.0000000000001052.Peer-Reviewed Original ResearchSystemic sclerosisClinical trial endpointsInflammatory bowel diseaseTrial endpointsAssessment of disease activityRisk stratification methodsGastrointestinal (GIDisease activityRisk stratificationEffective therapyImmune responseBowel diseaseDisease pathogenesisTherapeutic interventionsGastrointestinal diseasesOrgan systemsDiseaseMultidisciplinary teamPathogenesisFunctional studiesGut microbiomeEndpointSclerosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply